Funded Project Details - FY2021
|Title:|| Relaxin and PPAR gamma Activation for Liver Disease Treatment|
Robert G. Bennett
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2016 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
DESCRIPTION (provided by applicant): Hepatic fibrosis is a progressive condition resulting from a number of causes, including hepatitis, alcohol abuse, and nonalcoholic steatohepatitis, which can ultimately lead to cirrhosis and liver failure. Cirrhosis affects 900,000 persons, and the underlying causes (alcohol abuse and hepatitis infection) are more prevalent in the veteran population. There are currently few treatment options. Our previous studies showed that the hormone relaxin i...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.